Impact of a Structured Report Template on the Quality of CT and MRI Reports for Hepatocellular Carcinoma Diagnosis

Size: px
Start display at page:

Download "Impact of a Structured Report Template on the Quality of CT and MRI Reports for Hepatocellular Carcinoma Diagnosis"

Transcription

1 Impact of a Structured Report Template on the Quality of CT and MRI Reports for Hepatocellular Carcinoma Diagnosis Jeremy Ganeles 1, Tulay Ekinci 1, Milana Flusberg 1, Viktoriya Paroder 1, Mariya Kobi 1, Shlomit Goldberg-Stein 1, Victoria Chernyak 1 1 Montefiore Medical Center, Bronx, NY 1 The authors have no financial disclosures

2 Introduction LI-RADS developed in 2011 and updated in 2014 to standardize an algorithm and lexicon for interpretation and reporting of CT/MRIs in patients at risk for HCC Diagnostic algorithm based on defined major and ancillary imaging features, but no specific recommendations provided on how to report these features Structured reports has been shown to demonstrate greater clarity and comprehensive content when compared to free-text reports Similarly shown to be preferred by both referring clinicians and radiologist

3 Purpose To assess the impact of implementing a Liver Imaging Reporting and Data System (LI-RADS) structured reporting template on the quality of MRI reports for hepatocellular carcinoma

4 Methods: Background Structured LIRADS introduced at Montefiore in 4/2015; accompanied by LI- RADS training Template includes Observation identifier Location (Couinaud segment) Pick lists for all LI-RADS major features: Arterial Phase Hyperenhancement (APHE): yes/no Washout (WO): yes/no Capsule : yes/no Diameter Threshold Growth (TG): yes/no/n/a > Final LI-RADS category

5 LIRADS Template

6 Methods Retrospective IRB approved study Included reports of CTs and MRIs from 9/2014 to 2/2016 Free-text reports Structured LI-RADS reports Included only "Probable" and "Definite" HCC lesions (i.e. LR- 4 and LR-5) or equivalent descriptors in free-text reports Presence or absence of each or the following was recorded for each observation: LI-RADS category Couinaud segment Major LI-RADS HCC features: APHE WO Diameter Threshold growth Capsule At least one image number provided

7 Methods Free-text reports were compared with structured template report for whether presence or absence of each of the assessed variables was unequivocally reported Logistic regression models with binary outcomes of unequivocal reporting of each of the variables were constructed

8 Results Template (n=181) Free-text (n=125) p Value Age (years; mean and standard deviation) 63.0 (8.1) 63.6 (7.9) Sex (n, % male) 131 (72.4) 85 (68.0) Cause of liver disease (n, %) Hepatitis C Cirrhosis, NOS Hepatitis B Alcoholic cirrhosis Primary biliary cirrhosis Hepatitis C and B 99 (54.7) 65 (35.9) 9 (5.0) 5 (2.8) 0 (0.0) 3 (1.7) 87 (69.6) 26 (20.8) 3 (2.4) 7 (5.6) 2 (1.6) 0 (0.0) Modality (n, % MR) 164 (90.6) 100 (80.0) Description of lesion Definite HCC Probable HCC HCC Compatible with HCC Consistent with HCC Likely HCC Typical of HCC Suspicious for HCC Concerning for HCC 74 (40.9) 97 (53.6) 2 (1.1) 1 (0.6) 2 (1.1) 2 (1.1) 2 (1.1) 0 (0) 1 (0.6) 0 (0) 3 (2.4) 11 (8.8) 11 (8.8) 51 (40.8) 5 (4.0) 21 (16.8) 16 (12.8) 7 (5.6) <0.001

9 Results Variable Template (n=181) Free-text (n=125) p Value LI-RADS category 178 (98.3) 23 (18.4) <0.001 Couinaud segment 181 (100) 102 (81.6) <0.001 Diameter 181 (100) 118 (94.4) Presence/absence of TG 140 (77.4) 14 (11.2) <0.001 unequivocally reported Presence/absence of APHE 177 (97.8) 101 (80.8) <0.001 unequivocally reported Presence/absence of WO 178 (98.3) 93 (74.4) <0.001 unequivocally reported Presence/absence of capsule 176 (97.2) 24 (19.2) <0.001 unequivocally reported At least image number reported 181 (100) 81 (64.8) <0.001 Reported as n (%)

10 Results Outcome variable Odds Ratio 95% CI p Value LI-RADS category reported <0.001 Presence/absence of TG unequivocally <0.001 reported Presence/absence of APHE unequivocally reported <0.001 Presence/absence of WO unequivocally <0.001 reported Presence/absence of capsule unequivocally reported <0.001 Adjusted for modality and cause of liver disease; free-text group as the reference

11 Discussion Structured reporting demonstrated more comprehensive and consistent reporting of the major HCC features and LI-RADS category Serves as a useful checklist for assessing liver lesions in at-risk patients Documentation of major HCC features is mandated by OPTN (Organ Procurement and Transplantation Network) for transplant candidates All imaging is re-interpreted by radiologists in transplant centers Adds cost and time More likely to use a scoring system and characterize a lesion as definite HCC at transplant center Substantial differences shown in MRI interpretations between transplant center and outside institution reads Implementation of structured reporting may help reduce discrepancies in HCC diagnosis between readers with varying experience and comfort, as well as increase the rate of reporting of all OPTN-required elements, thereby eliminating the need for re-interpretation.

12 Discussion Limitations: Study limited to Definite or Probable HCC End user satisfaction was not assessed Impact on patient management/outcome was not assesed Accuracy of reports not reviewed Conclusion Use of structured LI-RADS template results in more comprehensive and consistent reporting of major features of HCC and LI-RADS category compared with free-text.

Objectives. LI-RADS v2017. Working Groups. Cynthia Santillan. Released October 2014 Diagnosis. Screening/ Surveillance. Diagnosis

Objectives. LI-RADS v2017. Working Groups. Cynthia Santillan. Released October 2014 Diagnosis. Screening/ Surveillance. Diagnosis LR-NC Cynthia Santillan LR-TIV Objectives 1. To teach participants how to apply the Liver Imaging Reporting and Data System () to their interpretation of imaging studies for the evaluation of hepatocellular

More information

Talking To Your Hepatologists & Colleagues About LI-RADS. Joseph Yacoub MD & Claude Sirlin MD SCBT-MR 2017 Workshop

Talking To Your Hepatologists & Colleagues About LI-RADS. Joseph Yacoub MD & Claude Sirlin MD SCBT-MR 2017 Workshop Talking To Your Hepatologists & Colleagues About LI-RADS Joseph Yacoub MD & Claude Sirlin MD SCBT-MR 2017 Workshop What is LI-RADS? System for standardizing technique, interpretation, and reporting For

More information

Management. Chapter 11. Primary Author. Contributing Authors. University of Toronto & University of Ottawa. Illustrators & figure contributors

Management. Chapter 11. Primary Author. Contributing Authors. University of Toronto & University of Ottawa. Illustrators & figure contributors Chapter 11 Primary Author Donald G. Mitchell Thomas Jefferson University Contributing Authors Victoria Chernyak Ania Z. Kielar Yuko Kono Claude B. Sirlin Montefiore Medical Center University of Toronto

More information

LI-RADS Reporting. Chapter 14. Primary Authors. Contributing Authors. Memorial Sloan Kettering Cancer Center

LI-RADS Reporting. Chapter 14. Primary Authors. Contributing Authors. Memorial Sloan Kettering Cancer Center Chapter 14 LI-RADS Primary Authors Victoria Chernyak Mustafa R. Bashir Montefiore Medical Center Duke University Medical Center Contributing Authors Richard K. Do Aya Kamaya Ania Z. Kielar Donald G. Mitchell

More information

Liver Imaging Reporting and Data System LI-RADS v A Pictorial Review of the Categories on CT and MRI

Liver Imaging Reporting and Data System LI-RADS v A Pictorial Review of the Categories on CT and MRI Liver Imaging Reporting and Data System LI-RADS v2014 - A Pictorial Review of the Categories on CT and MRI Poster No.: C-1584 Congress: ECR 2017 Type: Educational Exhibit Authors: M. El Hawari, K. Ali,

More information

Objectives. HCC Incidence and Mortality. Disclosure Statement HCC. Imaging of Hepatocellular Carcinoma. Treatment of Hepatocellular Carcinoma

Objectives. HCC Incidence and Mortality. Disclosure Statement HCC. Imaging of Hepatocellular Carcinoma. Treatment of Hepatocellular Carcinoma Imaging of Hepatocellular Carcinoma and the use of LI RADS Treatment of Hepatocellular Carcinoma Aaron D. Anderson, D.O. AOCR April 2015 Objectives Show how the use of LI RADS can simplify the diagnosis

More information

Imaging-Based Diagnostic Systems for Hepatocellular Carcinoma

Imaging-Based Diagnostic Systems for Hepatocellular Carcinoma Gastrointestinal Imaging Review Cruite et al. Imaging-Based Diagnosis of Hepatocellular Carcinoma Gastrointestinal Imaging Review FOCUS ON: Irene Cruite 1 An Tang 2 Claude B. Sirlin 3 Cruite I, Tang A,

More information

Compute-aided Differentiation of Focal Liver Disease in MR Imaging

Compute-aided Differentiation of Focal Liver Disease in MR Imaging 1063 Compute-aided Differentiation of Focal Liver Disease in MR Imaging Xuejun Zhang a, Masayuki Kanematsu b, Hiroshi Fujita c, Takeshi Hara c, Hiroshi Kondo b, Xiangrong Zhou c, Wenguang Li a and Hiroaki

More information

CT/MRI LI-RADS v2017 CORE

CT/MRI LI-RADS v2017 CORE CT/MRI LI-RADS v2017 CORE Untreated observation without pathologic proof in patient at high risk for HCC If cannot be categorized due to image degradation or omission If definite tumor in vein (TIV) If

More information

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis

DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care

More information

HCC and mass effect. Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? What you need to know about AFP.

HCC and mass effect. Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? What you need to know about AFP. Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? Arun J Sanyal M.B.B.S., M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University Imaging features used

More information

Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm

Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm pissn 2287-2728 eissn 2287-285X Liver Imaging Clinical and Molecular Hepatology 2016;22:296-307 Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic

More information

PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good

PEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision

More information

MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA

MRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA MRI for HCC surveillance and reporting: LI-RADS Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA Cirrhotic Nodules Regenerative Nodule Atypical Nodule Hyperplastic Nodule Dysplastic

More information

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center

Hepatobiliary Malignancies Retrospective Study at Truman Medical Center Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which

More information

Modern liver imaging techniques - A new era in liver ultrasound

Modern liver imaging techniques - A new era in liver ultrasound Modern liver imaging techniques - A new era in liver ultrasound Yuko Kono, M.D., Ph.D. Clinical Professor Departments of Medicine and Radiology University of California, San Diego San Diego, USA How to

More information

Liver imaging reporting and data system: An expert consensus statement

Liver imaging reporting and data system: An expert consensus statement Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Liver imaging reporting and data system: An expert consensus statement Khaled M. Elsayes The University of

More information

Gastrointestinal Imaging Original Research

Gastrointestinal Imaging Original Research Gastrointestinal Imaging Original Research Potretzke et al. iphenotypic Primary Liver Carcinoma Gastrointestinal Imaging Original Research FOCUS ON: Theodora. Potretzke 1 enjamin R. Tan 2 Maria. Doyle

More information

US LI-RADS v2017 CORE

US LI-RADS v2017 CORE US LI-RADS v2017 CORE Screening or surveillance US in patient at high risk for HCC US category US-1 US-2 US-3 Negative Subthreshold Positive Category Concept Definition US-1 Negative US-2 Subthreshold

More information

LIVER IMAGING TIPS IN VARIOUS MODALITIES. M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly

LIVER IMAGING TIPS IN VARIOUS MODALITIES. M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly LIVER IMAGING TIPS IN VARIOUS MODALITIES M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly Hepatocellular carcinoma is a common malignancy for which prevention, screening, diagnosis,

More information

With recent advances in treatment of hepatocellular SPECIAL ARTICLE

With recent advances in treatment of hepatocellular SPECIAL ARTICLE SPECIAL ARTICLE LI-RADS (Liver Imaging Reporting and Data System): Summary, Discussion, and Consensus of the LI-RADS Management Working Group and Future Directions Donald G. Mitchell, 1 Jordi Bruix, 2

More information

AMSER Case of the Month: June 2018

AMSER Case of the Month: June 2018 AMSER Case of the Month: June 2018 64 year old male undergoing evaluation for liver transplant By Timothy Morgan, MS IV Lake Erie College of Osteopathic Medicine Jonathan Potts, MD Interventional Radiology,

More information

Newcastle HPB MDM updated radiology imaging protocol recommendations. Author Dr John Scott. Consultant Radiologist Freeman Hospital

Newcastle HPB MDM updated radiology imaging protocol recommendations. Author Dr John Scott. Consultant Radiologist Freeman Hospital Newcastle HPB MDM updated radiology imaging protocol recommendations Author Dr John Scott. Consultant Radiologist Freeman Hospital This document is intended as a guide to aid radiologists and clinicians

More information

9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES

9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report

More information

Peer Review in Radiology

Peer Review in Radiology Department of Radiology Massachusetts General Hospital Harvard Medical School Peer Review in Radiology Hani Abujudeh MD, MBA Associate Professor of Radiology Harvard Medical School Massachusetts General

More information

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION

NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION 1. A service development evaluation to transplant down-staged

More information

Surveillance for Hepatocellular Carcinoma

Surveillance for Hepatocellular Carcinoma Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April

More information

Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template

Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template Abstract #17-130 ACR Annual Meeting 2017 Presenting Author: Whitney

More information

Validation of Clinical Outcomes in Electronic Data Sources

Validation of Clinical Outcomes in Electronic Data Sources Validation of Clinical Outcomes in Electronic Data Sources Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Center for Clinical Epidemiology and Biostatistics Center for Pharmacoepidemiology

More information

The Focal Hepatic Lesion: Radiologic Assessment

The Focal Hepatic Lesion: Radiologic Assessment The Focal Hepatic Lesion: Radiologic Assessment Kevin Kuo, Harvard Medical School Year III Our Patient: PS 67 y/o female w/ long history of alcohol use Drinking since age 18, up to one bottle of wine/day

More information

Reinterpretation of Outside Hospital MRI Abdomen Examinations in Patients With Cirrhosis: Is the OPTN Mandate Necessary?

Reinterpretation of Outside Hospital MRI Abdomen Examinations in Patients With Cirrhosis: Is the OPTN Mandate Necessary? Gastrointestinal Imaging Original Research Rahman et al. Reinterpretation of MRI Examinations in Cirrhosis Gastrointestinal Imaging Original Research W. Tania Rahman 1, 2 Hero K. Hussain 3 Neehar D. Parikh

More information

Critical Review Form Clinical Decision Analysis

Critical Review Form Clinical Decision Analysis Critical Review Form Clinical Decision Analysis An Interdisciplinary Initiative to Reduce Radiation Exposure: Evaluation of Appendicitis in a Pediatric Emergency Department with Clinical Assessment Supported

More information

Hepatic Imaging: What Every Practitioner Should Know

Hepatic Imaging: What Every Practitioner Should Know Hepatic Imaging: What Every Practitioner Should Know Shuchi K. Rodgers, MD Section Chief, Abdominal Imaging Director of Ultrasound Department of Radiology Einstein Medical Center rodgerss@einstein.edu

More information

Repeatability of Diagnostic Features and Scoring Systems for Hepatocellular Carcinoma by Using MR Imaging 1

Repeatability of Diagnostic Features and Scoring Systems for Hepatocellular Carcinoma by Using MR Imaging 1 Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Original Research

More information

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT

HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%

More information

LI-RADS v2016 Key Dates

LI-RADS v2016 Key Dates Key Dates April 2014: ACR CEUS LI-RADS working group was formed Chair: Yuko Kono, Co-chair: Andrej Lyshchik Members: David Cosgrove, Christoph Dietrich, Hyun-Jung Jang, Tae Kim, Fabio Piscaglia, Claude

More information

Timothy L. Miao 1, Ania Z. Kielar 2,3, Rebecca M. Hibbert 2, Nicola Schieda 2,3

Timothy L. Miao 1, Ania Z. Kielar 2,3, Rebecca M. Hibbert 2, Nicola Schieda 2,3 DOES LESION T1 SIGNAL INTENSITY RELATIVE TO LIVER PARENCHYMA PREDICT VISIBILITY ON ULTRASOUND? A clinical tool to determine feasibility of ultrasound-guided percutaneous interventions Timothy L. Miao 1,

More information

Spiculated breast masses on MRI: Which category should we choose, 4 or 5?

Spiculated breast masses on MRI: Which category should we choose, 4 or 5? Spiculated breast masses on MRI: Which category should we choose, 4 or 5? Poster No.: C-1394 Congress: ECR 2015 Type: Scientific Exhibit Authors: N. Onishi, S. Kanao, M. Kataoka, M. Kawai, M. Iima, A.

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 143 Effective Health Care Program Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma Executive Background and Objectives Hepatocellular carcinoma

More information

Alice Fung, MD Oregon Health and Science University

Alice Fung, MD Oregon Health and Science University Alice Fung, MD Oregon Health and Science University Disclosure Comments The speaker Alice Fung, MD Has relevant financial relationships to disclose. Received honorarium from (Guerbet). This individual

More information

Diagnosis of Liver Tumor Using 3D Segmentation Method for Selective Internal Radiation Therapy

Diagnosis of Liver Tumor Using 3D Segmentation Method for Selective Internal Radiation Therapy Diagnosis of Liver Tumor Using 3D Segmentation Method for Selective Internal Radiation Therapy K. Geetha & S. Poonguzhali Department of Electronics and Communication Engineering, Campus of CEG Anna University,

More information

SCBT-MR 2015 LungRADS : Basics

SCBT-MR 2015 LungRADS : Basics SCBT-MR 2015 LungRADS : Basics Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality reduction 6.9% all cause mortality

More information

Critical reading of diagnostic imaging studies. Lecture Goals. Constantine Gatsonis, PhD. Brown University

Critical reading of diagnostic imaging studies. Lecture Goals. Constantine Gatsonis, PhD. Brown University Critical reading of diagnostic imaging studies Constantine Gatsonis Center for Statistical Sciences Brown University Annual Meeting Lecture Goals 1. Review diagnostic imaging evaluation goals and endpoints.

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

The Diagnosis of Hypovascular Hepatic Lesions Showing Hypo-intensity in the Hepatobiliary Phase of Gd-EOB- DTPA-enhanced MR Imaging in High-risk

The Diagnosis of Hypovascular Hepatic Lesions Showing Hypo-intensity in the Hepatobiliary Phase of Gd-EOB- DTPA-enhanced MR Imaging in High-risk 2013 67 4 239 244 The Diagnosis of Hypovascular Hepatic Lesions Showing Hypo-intensity in the Hepatobiliary Phase of Gd-EOB- DTPA-enhanced MR Imaging in High-risk Patients for Hepatocellular Carcinoma

More information

Hepatocellular Carcinoma: Diagnosis and Management

Hepatocellular Carcinoma: Diagnosis and Management Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm

More information

Prevalence of adrenal incidentaloma a methodologic comparison of EMR query strategies

Prevalence of adrenal incidentaloma a methodologic comparison of EMR query strategies Prevalence of adrenal incidentaloma a methodologic comparison of EMR query strategies Michio Taya, BA 1 ; Viktoriya Paroder, MD, PhD 2 ; Eran Bellin, MD 3,4 ; Linda Haramati, MD, MS 2,3 2 Departments of

More information

Gemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis

Gemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis GE Healthcare Gemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis CT clinical case study lesion characterization Desiree Morgan, MD Vice Chair of Clinical Research Professor

More information

Screening for Hepatoma and an Introduction to LIRADS

Screening for Hepatoma and an Introduction to LIRADS Screening for Hepatoma and an Introduction to LIRADS Helena Gabriel, MD Associate Professor of Radiology Director, School of Ultrasound rthwestern University Feinberg School of Medicine Chicago, IL Overview

More information

2/21/2014. Disclosure statement CT, MRI, LI-RADS. CT and MRI as first-line modalities PLAN. CT- and MRI-based diagnosis. Role of CT and MRI

2/21/2014. Disclosure statement CT, MRI, LI-RADS. CT and MRI as first-line modalities PLAN. CT- and MRI-based diagnosis. Role of CT and MRI Ancillary features that may favor HCC LR1 LR2 LR3 LR4 LR5 Ancillary features that may favor benignity,, LI-RADS An Tang, MD, MSc CHUM, University of Montreal CASL HCC Meeting: Consensus, Controversies

More information

Alexander Lankowski 1, Cedric Bien 1,2, Richard Silvera 1,2, Viraj Patel 1, Uriel Felsen 3, Oni Blackstock 1

Alexander Lankowski 1, Cedric Bien 1,2, Richard Silvera 1,2, Viraj Patel 1, Uriel Felsen 3, Oni Blackstock 1 Alexander Lankowski 1, Cedric Bien 1,2, Richard Silvera 1,2, Viraj Patel 1, Uriel Felsen 3, Oni Blackstock 1 1 Division of General Internal Medicine, Montefiore Health System & Albert Einstein College

More information

The Management of Advanced Stage Hepatocellular Carcinoma

The Management of Advanced Stage Hepatocellular Carcinoma The Management of Advanced Stage Hepatocellular Carcinoma Pierce K.H Chow MD PhD Professor, Duke-NUS Graduate Medical School Singapore Senior Consultant Surgeon, National Cancer Center Singapore Senior

More information

The pediatric end-stage liver disease (PELD) score

The pediatric end-stage liver disease (PELD) score Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability

More information

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)

Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer

More information

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation

HCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine

More information

Evaluation Process for Liver Transplant Candidates

Evaluation Process for Liver Transplant Candidates Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection

More information

Discrepancy between the nonautomatic

Discrepancy between the nonautomatic Discrepancy between the nonautomatic and semiautomatic measurements of AAA diameter-does it influence outcome? Joy Roy Department of Vascular Surgery Karolinska University Hospital / Karolinska Institutet

More information

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice

Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Structured Reporting of Multiphasic CT for Hepatocellular Carcinoma: Effect on Staging and Suitability for Transplant

Structured Reporting of Multiphasic CT for Hepatocellular Carcinoma: Effect on Staging and Suitability for Transplant Gastrointestinal Imaging Original Research Poullos et al. Multiphasic CT Reporting for HCC Gastrointestinal Imaging Original Research Peter D. Poullos 1 Joseph J. Tseng 1 Marc L. Melcher 2 Waldo Concepcion

More information

SIR- RFS Journal Primer

SIR- RFS Journal Primer Comparison of Combina-on Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboliza-on with Radiofrequency Abla-on versus Microwave Abla-on SIR- RFS Journal Primer Quick Summary

More information

Staging & Current treatment of HCC

Staging & Current treatment of HCC Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt

More information

Liver Tumors. Prof. Dr. Ahmed El - Samongy

Liver Tumors. Prof. Dr. Ahmed El - Samongy Liver Tumors Prof. Dr. Ahmed El - Samongy Objective 1. Identify the most important features of common benign liver tumors 2. Know the risk factors, diagnosis, and management of hepatocellular carcinoma

More information

Workup of a Solid Liver Lesion

Workup of a Solid Liver Lesion Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any

More information

Copyright 2007 IEEE. Reprinted from 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, April 2007.

Copyright 2007 IEEE. Reprinted from 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, April 2007. Copyright 27 IEEE. Reprinted from 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, April 27. This material is posted here with permission of the IEEE. Such permission of the

More information

Liver Transplantation Evaluation: Objectives

Liver Transplantation Evaluation: Objectives Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation

More information

Locoregional Therapy for Hepatoma

Locoregional Therapy for Hepatoma Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish

More information

Radiation burden of hepatocellular carcinoma screening program in hepatitis B virus patients should we recommend magnetic resonance imaging instead?

Radiation burden of hepatocellular carcinoma screening program in hepatitis B virus patients should we recommend magnetic resonance imaging instead? Radiation burden of hepatocellular carcinoma program in hepatitis B virus patients should we recommend magnetic resonance imaging instead? Background: Current Hepatocellular Carcinoma (HCC) surveillance

More information

Liver resection for HCC

Liver resection for HCC 8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the

More information

Need for long-term evaluation of therapy in Chronic Hepatitis B

Need for long-term evaluation of therapy in Chronic Hepatitis B Need for long-term evaluation of therapy in Chronic Hepatitis B VHPB meeting Budapest 18/03/2010 Solko Schalm & Mehlika Toy Licensed Therapy Chronic hepatitis B Drug Date of Efficacy Disease Clinical Mortality

More information

Patient referral for elective coronary angiography: challenging the current strategy

Patient referral for elective coronary angiography: challenging the current strategy Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology

More information

Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center

Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center Liver Tumors Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center Differential Diagnosis Malignant Metastatic from non-hepatic primary Hepatocellular carcinoma Cholangiocarcinoma Biliary cystcarcinoma

More information

US-Guided Radiofrequency Ablation of Hepatic Focal Lesions

US-Guided Radiofrequency Ablation of Hepatic Focal Lesions US-Guided Radiofrequency Ablation of Hepatic Focal Lesions Poster No.: C-2219 Congress: ECR 2011 Type: Scientific Exhibit Authors: D. Armario Bel, A. PLA, F. TERREL, X. Serres; BARCELONA/ES Keywords: Neoplasia,

More information

Disparities in Liver Transplant Allocation: An Update on MELD Allocation System

Disparities in Liver Transplant Allocation: An Update on MELD Allocation System Disparities in Liver Transplant Allocation: An Update on MELD Allocation System Naudia L. Jonassaint, MD MHS Assistant Professor of Medicine and Surgery University of Pittsburgh School of Medicine Historical

More information

MSK MRI Protocol Standardization:

MSK MRI Protocol Standardization: MSK MRI Protocol Standardization: Impact on patient care and finances across a large health care system Manickam Kumaravel, M.D. Thomas Connors, B.B.A. No financial disclosures Purpose To evaluate the

More information

Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430

Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option

More information

Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review

Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review Gastrointestinal Imaging Review rslanoglu et al. Guidelines on Hepatocellular Carcinoma Gastrointestinal Imaging Review tilla rslanoglu 1 deel R. Seyal Faezeh Sodagari zize Sahin Frank H. Miller Riad Salem

More information

EASL-EORTC Guidelines

EASL-EORTC Guidelines Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according

More information

Definition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period

Definition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period Quality ID #387 (NQF 3060): Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL

More information

간암의조직검사 : 언제, 어떻게? 계명대학교의과대학내과학교실 정우진

간암의조직검사 : 언제, 어떻게? 계명대학교의과대학내과학교실 정우진 간암의조직검사 : 언제, 어떻게? 계명대학교의과대학내과학교실 정우진 간생검한다 vs 안한다? M/81 Alcoholic LC, albumin 4.0, bil 0.6, Cr 1.06, glucose 141, afp 2.2, CA19-9 12.41 CT: R/O HCC in S8, R/O CC M/69 HBV(-), HCV(-), social alcoholics

More information

CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners

CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners Review Article CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners Francesca Patella 1, Filippo Pesapane* 1, Enrico Maria Fumarola 1, Ilaria Emili 1, Riccardo Spairani 1, Salvatore Alessio Angileri

More information

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD

Interventional Radiology in Liver Cancer. Nakarin Inmutto MD Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT

More information

Contrast Enhanced Ultrasound of Parenchymal Masses in Children

Contrast Enhanced Ultrasound of Parenchymal Masses in Children Contrast Enhanced Ultrasound of Parenchymal Masses in Children Sue C Kaste, DO On behalf of Beth McCarville, MD St. Jude Children s Research Hospital Memphis, TN Overview Share St. Jude experience with

More information

Liver imaging takes a step forward with Ingenia

Liver imaging takes a step forward with Ingenia Publication for the Philips MRI Community ISSUE 49 2013 / 2 Liver imaging takes a step forward with Ingenia Lyon South Hospital strives to move from several studies first CT, then MR or PET to using just

More information

Computer based delineation and follow-up multisite abdominal tumors in longitudinal CT studies

Computer based delineation and follow-up multisite abdominal tumors in longitudinal CT studies Research plan submitted for approval as a PhD thesis Submitted by: Refael Vivanti Supervisor: Professor Leo Joskowicz School of Engineering and Computer Science, The Hebrew University of Jerusalem Computer

More information

Financial Disclosure

Financial Disclosure Benign Liver Masses Adil Abdalla, MBBS Creighton University-CHI Health August 25, 2018 Financial Disclosure Nothing to disclose Financial Disclosure 1 Objectives To assess patients with benign liver tumors

More information

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma Surveillance Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated

More information

Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial

Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial Amit G. Singal MD MS UT Southwestern Medical Center and Parkland Health & Hospital System Dallas, TX, USA 1

More information

Screening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering

Screening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this

More information

HEPATOCYTE SPECIFIC CONTRAST MEDIA: WHERE DO WE STAND?

HEPATOCYTE SPECIFIC CONTRAST MEDIA: WHERE DO WE STAND? HEPATOCYTE SPECIFIC CONTRAST MEDIA: WHERE DO WE STAND? Andrew T. Trout, MD @AndrewTroutMD Disclosures No relevant disclosures Outline Review of hepatocyte specific contrast media Review of hepatocellular

More information

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance

Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,

More information

LI-RADS Populations: Surveillance, Diagnosis, Staging, Treatment Response

LI-RADS Populations: Surveillance, Diagnosis, Staging, Treatment Response Chapter 2 LI-RADS Populations: Surveillance, Diagnosis, Staging, Treatment Response Primary Author An Tang University of Montreal Contributing Authors Victoria Chernyak Oussama Hallouch Aya Kamaya Claude

More information

AllinaHealthSystems 1

AllinaHealthSystems 1 Disclosure I have no financial relationships to disclose. Dimensions in Oncology 2017 Liver Cancers Jill May, BSN, RN, OCN Hepatobiliary Cancer Care Coordinator 1 LIVER ~ Where and what is it? Located

More information

THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)

THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC) MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA

More information

FAQs for HCP segment New Instructions for Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System Non-Adjunctive Indication

FAQs for HCP segment New Instructions for Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System Non-Adjunctive Indication FAQs for HCP segment New Instructions for Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System Non-Adjunctive Indication Q1. The Dexcom G5 Mobile System is the first CGM System to receive FDA approval

More information

Multiple Primary Quiz

Multiple Primary Quiz Multiple Primary Quiz Case 1 A 72 year old man was found to have a 12 mm solid lesion in the pancreatic tail by computed tomography carried out during a routine follow up study of this patient with adult

More information

Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Jorge A. Marrero, MD, MS, MSHM; Laura M. Kulik, MD; Claude

More information

Hepatocellular carcinoma in Sri Lanka - where do we stand?

Hepatocellular carcinoma in Sri Lanka - where do we stand? SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior

More information

Computer-Aided Evaluation of Malignancy with Magnetic Resonance Imaging of the Breast. Original Policy Date

Computer-Aided Evaluation of Malignancy with Magnetic Resonance Imaging of the Breast. Original Policy Date MP 6.01.36 Computer-Aided Evaluation of Malignancy with Magnetic Resonance Imaging of the Breast Medical Policy Section Radiology Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed

More information

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the

More information